A Prospective Observational Multicenter Study of HF10 Therapy in Patients who Previously Railed Traditional SCS (RENEW)

Grants and Contracts Details

StatusFinished
Effective start/end date9/27/18 → 7/7/21

Funding

  • Nevro Corporation: $15,991.00